Redefining Noninvasive
Ocular Therapeutics
News Releases and Corporate Updates
Our Blog
Our Blog
An ongoing series of informational entries
An ongoing series of informational entries
December 6, 2018
Ophthalmology researchers discuss the first in human phase 1/2 clinical study and data of DSP-Visulex.
October 11, 2019
Aciont was issued a U.S. patent that covers an important aspect of the novel design of its main Visulex ocular drug delivery system which has been tested for safety and efficacy in its lead clinical program under U.S. IND.
April 15, 2020
Ophthalmology researchers led by Molokhia et. al discuss various animal models (PK and efficacy) demonstrating the delivery of macromolecules using process known as electroosmosis.
Our Blog
Our Blog
An ongoing series of informational entries
An ongoing series of informational entries
March 7, 2018
Papangkorn and colleagues discuss drug transport kinetics and safety with respect to a wide variety of treatment modalities (treatment time duration and concentration/formulation) with DSP-Visulex.
Aciont Executives To Present and Participate at the 10th Ocular Diseases Drug Discovery Conference
Aciont Executives To Present and Participate at the 10th Ocular Diseases Drug Discovery Conference
March 8, 2018
Aciont will be one of three emerging companies showcased at the 10th Ocular Diseases Drug Discovery Conference organized by GTCbio is scheduled for March 20-21, 2018 in San Diego, CA. John Higuchi will be presenting Aciont's story on Day 2 of the event, March 21 around 12:55 PM. Dr. Balbir Brar will be participating during a special panel discussion on regulatory topics starting earlier in the day at 9:20 AM.
March 9, 2018
Dr. Kongnara Papangkorn, Aciont's Vice President of Product Development, will present findings from DSPV-201, a randomized, parallel group, double-masked, active controlled phase 1/2 clinical trial of dexamethasone sodium phosphate using the Visulex-P non invasive ocular drug delivery system. See Kongnara's abstract.
Archived News
Archived News
An ongoing series of informational entries
An ongoing series of informational entries
December 2014
This article announced the enrollment of non infections anterior uveitis patients in DSPV-201, a randomized, parallel group, double-masked, active controlled phase 1/2 clinical trial of dexamethasone sodium phosphate using the Visulex-P non invasive ocular drug delivery system.
November 2017
John Higuchi presented a summary of Aciont's Visulex technologies at the OIS Conference in New Orleans, LA.
November 2017
DSP Visulex treatment modalities were tested in a pan uveitis model in rabbit. The paper summarizes both efficacy and safety results in response to such DSP Visulex treatments.
Our Blog
Our Blog
An ongoing series of informational entries
An ongoing series of informational entries
May, 2013
Aciont received a second phase 2 SBIR grant (a phase 2b) to support the clinical development of DSP Visulex. Total funds from the National Eye Institute toward the support for DSP Visulex was about $4.4 million.